Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 studyBRITISH JOURNAL OF CANCERIF6.82023-07-085OA
The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort StudyJOURNAL OF CANCERIF3.22023-01-013OAAI
Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort StudyFRONTIERS IN ONCOLOGYIF3.32021-10-2719OAAI
Elevated Platelet Count is Associated with Poor Survival After Transarterial Chemoembolization Treatment in Patients with Hepatocellular Carcinoma: A Cohort StudyJOURNAL OF HEPATOCELLULAR CARCINOMAIF3.42020-10-0111OAAI
CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2APOPTOSISIF8.12013-03-0619PREAI
Overexpression of CIAPIN1 inhibited pancreatic cancer cell proliferation and was associated with good prognosis in pancreatic cancerCANCER GENE THERAPYIF52012-06-0817OAAI
CacyBP/SIP Protein Promotes Proliferation and G1/S Transition of Human Pancreatic Cancer CellsMOLECULAR CARCINOGENESISIF3.22011-01-2530OA
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项